Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
AlzChem is a prominent specialty chemical company headquartered in Germany, widely recognized in the life sciences sector as "The Original Creatine Patent Company." The company is the sole manufacturer of Creapure, a premium, high-purity creatine monohydrate produced through a proprietary chemical synthesis route that ensures the absence of harmful impurities. Beyond sports nutrition, AlzChem provides essential intermediates and active pharmaceutical ingredients (APIs) for the healthcare industry, leveraging its expertise in N-C-N chemistry. Their portfolio includes products for muscle health, metabolic support, and agricultural applications. As a publicly traded entity on the Frankfurt Stock Exchange, AlzChem maintains a global presence with a focus on sustainable and high-quality chemical production. The company continues to support clinical research into the therapeutic benefits of creatine for neurological and age-related conditions.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on The Original Creatine Patent Company.